

PERCEVAL[™] PLUS



The optimal mix

AORTIC PERICARDIAL HEART VALVE





PERCEVAL[™] PLUS

An ideal solution for minimally invasive surgery, makes sutureless aortic¹ valve replacement available to a wide patient population^{*2}



PERCEVAL[™] IS A TRUSTED PLATFORM THAT HAS ACHIEVED THE FOLLOWING MILESTONES:

- First-in-human performed in 2007
- More than 11 years of successful clinical use³
- Solid clinical evidence
- Truly global reach

* The Perceval Plus is an improvement of the proven Perceval technology. Perceval clinical data can be used as reference for Perceval Plus.



THE OPTIMAL MIX - Unique Valve Design




The decision to make a transcatheter aortic valve implantation in Perceval Plus compared to other options should be done by the Heart team based on individual assessment of the patient's conditions. The safety and efficacy of Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in the other prosting to radia perceval in patients should be performed to cases in which the beenfits or sunging Perceval Perceval valve in valve the beenfits or sunging Perceval valve in valve the radis. The available clinical data indicate that using Perceval in patients should be interference with the other prostheses.



Unique Valve Design

THE PERCEVAL VALVE DESIGN HAS A LONG CLINICAL HERITAGE. Its proven double-sheet design has been used to manufacture biological prostheses since 1985, while the super elastic stent provides unique characteristics and mechanical behavior. With Perceval Plus, the valve is enhanced with a reduced ventricular protrusion feature, designed to further improve patient outcomes.



Reduced valve ventricular protrusion


The reduction of the protrusion of the valve below the aortic annulus is expected to decrease the risk of impairment of the atrio-ventricular conduction system.



Facilitates Minimally Invasive Surgery

THE ATRAUMATIC COLLAPSING DOES NOT IMPAIR LEAFLET FUNCTIONALITY,[®] PREVENTING POSSIBLE DAMAGE TO THE TISSUE.² When

collapsed, the valve allows the surgeon better visibility of the annulus and the anatomical structures during implantation and deployment, for greater confidence and faster, more precise positioning at the implantation site.¹





Designed for Durability


BASED ON A CLINICALLY PROVEN TECHNOLOGY. Perceval Plus is based on the trusted Perceval platform supported by more than 11 years of clinical experience that demonstrates excellent results in terms of durability.³





INNOVATIVE FREE TISSUE TREATMENT. The innovative FREE tissue treatment in Perceval Plus addresses both major causes of valve calcification, phospholipids and aldehydes.⁹

The technology also allows the valve to be stored in an aldehyde-free solution, resulting in negligible toxicity for the patient and a faster procedure for the surgeon as no rinsing is required.⁹




* vs control group9



Available to a Wide Patient Population

PERCEVAL PLUS CIVES PATIENTS EVEN BROADER TREATMENT OPTIONS FOR THEIR FUTURE. Its exclusive stent design allows even circumferential expansion to accommodate future transcatheter valves, making Perceval Plus a unique foundation for Valve-in-Valve procedures.*




* The decision to make a transcatheter aortic valve implantation in Perceval Plus compared to other options should be done by the Heart team based on individual assessment of the patient's conditions. The safety and efficacy of Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve should be performed according to indications provided by the transcatheter valve manufacturer.



Multiple Valve and Complex Procedures

PERCEVAL PLUS: WHEN TIME REALLY MATTERS. The unique characteristics of Perceval Plus make it an ideal choice in complex implantations⁵ while extending the benefits to a wider patient population.**

Whether using an open or a minimally invasive cardiac surgery (MICS) approach, Perceval Plus enables a faster procedure and reduced crossclamp time compared to traditional valve prostheses.⁵¹⁶



Perceval Plus helps reduce complexity even in challenging and time consuming procedures, while maintaining good hemodynamic outcomes.⁴⁵ Perceval Plus is safe and effective, even in cases of concomitant cardiac procedures.^{** 45}

" The decision of using Perceval in patients should be based on a careful individual assessment and limited to cases in which the benefits of using Perceval justify the risks. The available clinical data indicate that using Perceval in patients with other prostheses may result in intraoperative valve misplacement or insufficient leaflet coaptation leading to valve replacement, due to possible interference with the other prostheses.



Providing a Professional Support Network for Surgeons

CORCYM OFFERS A FULL RANGE OF TRAINING AND EDUCATION PROGRAMS FOR CARDIAC SURGEONS, AT ALL EXPERIENCE LEVELS TO SHARE BEST PRACTICES AND DEEPEN EXPERTISE.

The Perceval proctorship is a unique opportunity to gain first-hand experience and exchange knowledge with a network of expert Perceval users.

Educational opportunities include: dry-labs, in-OR proctorship and lectures.

A number of online and offline training and educational resources are also available to support surgeons in each step of their experience with Perceval Plus.

Visit our website for more details: www.corcym.com

PRODUCT ORDERING INFORMATION

CODE	DESCRIPTION	USE
PVF-S	PERCEVAL PLUS size S	
PVF-M	PERCEVAL PLUS size M	Single use
PVF-L	PERCEVAL PLUS size L	Single use
PVF-XL	PERCEVAL PLUS size XL	

ACCESSORIES ORDERING INFORMATION

CODE	DESCRIPTION		USE	
ICV 1232	Dual Collapser base S/M/L/XL		Re-usable	i dest
ICV 1219	Sizer S/M/L/XL		Re-usable	
0218TS	Inflation Device S/M/L/XL		Single use	Cree
ICV1345		S	Single use	-
ICV1346	ACCESSORY KIT	М		
ICV1347	 (Dual Collapser, Dual Holder, MICS Post-dilation Catheter) 	L		
ICV1348		XL		
ICV 1349	MICS ACCESSORY KIT (Dual Collapser, Dual MICS Holder, MICS Post-dilation Catheter)	S	Single use	
ICV 1350		Μ		1445
ICV 1351		L		
ICV 1352		XL		

REFERENCES

- Gluber M. et al. "International Expert Consensus on Sutureless and Rapid Deployment Valves in Aortic Valve Replacement Using Minimally Invasive Approaches' Innovations (Surgery 50 (2016) 1204-1205
 Los A et al. "Minimally invasive approach for eortic and mitral valve surgery." *European Journal of Cardio-Thoracic Surgery 50 (2016)* 1204-1205
 Meuris et al. "Sturreless ANR Experience in a Single Centre: 11 Years of Use In 468 Patients." *AAIS 2009 presents Bearing*." *Euro Cardiothoracic Surgery 50 (2016)* 1204-1205
 Cerask R. et al. "Sturreless, rapid deployment valves and stenet bioprosthesis in aortic valve replacement: ecommendations of an International Expert Concensus Panel: "*European Journal of Cardio-Thoracic Surgery 50 (2016)* 1204-1205
 Della Barbera et al. "Pre-implantation collapse in the Sorin Perceval 3.
 Della Barbera et al. "Sturreless, rapid deployment valves and stenet bioprosthesis in aortic valve replacement: recommendations of an International Expert Concensus Panel: "*European Journal of Cardio-Thoracic Surgery (SOI)* 1-00 duble 349:CFM-489
 Della Barbera et al. "Sturreless and traver replacement: a systematic review and meta-analysis." *Ann Cardiothorac Surg 2005*:1-00 dubles 202 (2003):224-827
 Della Barber Concensus Panel: "*European Journal of Cardio-Thoracic Surgery (SOI)* 1-00 dubles 202 (2003):224-827
 Meuris : "A novel tissue treatment to reduce mineralization of borin Thoracic Surgery (SOI) 1-00 dubles (SOI) 1-00 dubles et al. "Sturreless and treat et aplacement: a systematic review and meta-analysis." *Ann Cardiothorac Surg 2005*:4/21/100-111





INTENDED USE/INDICATIONS

INTENDED USE/INDICATIONS EUROPE: Perceav/Perceav/Plus prosthesis is intended to replace a damaged native aortic heart valve or a malfunctioning aortic prosthesis via open heart surgery. The prosthesis is indicated for use in adult patients suffering from aortic valve stenosis or steno-insufficiency or with a previously implanted aortic valve prosthesis that is no longer functioning adequately and requires replacement. Physicians should give careful consideration to the use of this valve in patients less than 65 years of age, as sample size in clinical studies for this patient population is insufficient to demonstrate a clinical benefit.

this patient population is insufficient to demonstrate a clinical benefit. US: The Perceval/Perceval Plus bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval/Perceval Plus bioprosthesis is intended for use in patients aged ≥ 65 years in which the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency.

KEY CONTRAINDICATIONS

Aneurysmal dilation or dissection of the ascending aortic wall; known hypersensitivity to nickel or cobalt alloys: ratio between the sinotubular junction and the annulus diameter greater than 1.3.

KEY WARNINGS

The TWARNINGS Do not under or oversize the prosthesis. This could result, in possible migration, excessive compression/ rupture of the aorta, suboptimal expansion or valve folding that may lead to fatal arrhythmia or hemorrhage, regurgitation or altered hemodynamics. Severe LVOT hypertrophy may prevent optimal expansion of the inflow portion of the stent.

TOP POTENTIAL SIDE EFFECTS TOP POTENTIAL SIDE EFFECTS Potential adverse events associated with cardiac valve replacement with a bioprosthesis and the related surgical procedure include: bleeding, cardiac conduction disorders, endocarditis, heart failure, neurological events, non structural dysfunction, structural valve deterioration, thromboembolism.

MRI conditional

For professional use. Instructions for Use are available upon request through the manufacturer's website. Not approved in all geographies. Consult your labeling.



Manufactured by:

Sorin Group Italia Srl Via per Crescentino sn 13040 Saluggia (VC) Italy Tel: +39 0161 487800 LivaNova Canada Corp. 5005 North Fraser Way Burnaby, BC V5J 5M1 Canada Tel: +604 412-5650

CE₀₁₂₃ © 2021 all rights reserved



CC-MK-00006 A